Skip to main content
OpenTrials
Completed

NCT Number: NCT06180213

Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma

The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through "Prion-like" mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network.

FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • presence of diagnosis of neurodegenerative disease.

Exclusion criteria

  • patients< 18 years

Treatment and study plan

FDG PET

Diagnostic Test

Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.

Primary outcomes

  1. FDG PET to measure brain areas of hypo or hyper regional metabolism in patients with neurodegenerative disease.

    Time frame: 4 years

    Characterization of the different pathologies examined starting from the study of regional metabolism in individual subjects up to the study of the functional activity of the different brain circuits.

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Registry information

Official study title

Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma: Retrospective Review of an Large Cohort of FDG PET Data

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Dec 22, 2023
Registry last updated
Dec 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.